sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Éñ¾­·¢Óý¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > Éñ¾­·¢Óý¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó

Ç°ÑÔ

Éñ¾­·¢ÓýÕÏ°­¼Ù˵ÒÔΪ£¬¾«ÉñÆÆËéÖ¢Ô´ÓÚÔçÆÚµÄÄÔËðÉË ¡£ÁÙ´²ÉÏ£¬¾«ÉñÆÆËéÖ¢·¢²¡ÓÚÇà׳Ä꣬ÓпÉÄÜÊÇÓÉÓÚÔçÆÚ´óÄÔËðÉ˵IJ¿Î»ÓëÕý³£·¢ÓýµÄÖÐÊàÉñ¾­ÏµÍ³Ö®¼äµÄÏ໥×÷ÓÃËù±¬·¢µÄ ¡£´óÄÔ·¢ÓýÉв»¿ÉÊì¶øÔâÓöËðÉ˵ÄÇéÐÎÏ£¬ÊÜËðÉ˲¿Î»½«ÔÚÒÔºóµÄ·¢ÓýÖиıäÓë´óÄÔÆäËû²¿Î»µÄÍŽ᷽·¨£¬¶ø±¬·¢Òì³£µÄÉñ¾­ÁªÂ磬ÕâÖÖÒì³£ÔÚ´óÄÔ·¢Óý³ÉÊìʱ±ãÌåÏÖ³öÀ´ ¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÃһϵÁÐÒªÁì¶ÔÐÂÉú´óÊó»ò·ÇÈËÁ鳤ÀàijЩÌض¨ÄÔÇøËð»Ù£¬Ö÷ÒªÊÇÆÆËðº£Âí·¢Óý£¬´Ó¶øÆÆËðº£Âí¼ÓÈëµÄÆÕ±éµÄƤÖʺÍƤÖÊÏÂÉñ¾­»·Â· ¡£ÕâЩËðÉË°üÀ¨Ö±½ÓͶÉ䵽ǰ¶îҶƤÖʵĺ£ÂíÇøÓò£¨È縹²àº£ÂíºÍ¸¹²àÏÂÍУ©£¬ÕâЩ²¿Î»¾ùÓ뾫ÉñÆÆËéÖ¢µÄ·¢²¡Ç×½üÏà¹Ø ¡£

¡¾Ä£×ÓÌص㡿£º

×дóÊ󸹲ຣÂí»ÙËðÄ£×ÓÒòº£ÂíµÄÐ˷ܶ¾ÐԵĻÙË𣬶øµ¼Ö³ÉÄê´óÊóÔÚÉñ¾­µÝÖʺÍÐÐΪ·½Ã汬·¢¸Ä±ä£¬ÈçÉç»áÐÔ½Ó´¥ÐÐΪïÔÌ­¡¢ÊÂÇéÓ°ÏóÕÏ°­¡¢¶ÔÓ¦¼¤ÐԴ̼¤µÄ¹ý¶àÐж¯ºÍ¿Ì°åÐÐΪµÄÔöÌí ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

Ó×Äê´óÊ󸹲ຣÂí»ÙËðÔÚÇ°¶îҶƤ²ã±¬·¢ÁËһϵÁеIJ¡ÀíÐԸı䣬È磬ÒÒõ£Ì춬°±ËáˮƽµÄϽµ¡¢Ó¦¼¤ÓÕ·¢¶à°Í°·(DA)ÊÍ·ÅϽµ¡¢¹È°±ËáתÔËÌåEAAC1Ƥ²ã±í´ïµÄïÔÌ­¡¢γ-°±»ù¶¡Ëá(gamma-amino butyric acid,GABA)ºÏ³ÉøïÔÌ­¡¢¹È°±ËáÍÑôÈøµÄïÔÌ­¡¢ÄÔÔ´ÐÔÉñı»®ÑøÒò×Ó(BDNF)µÄïÔÌ­¼°Ä³Ð©»ùÒòת¼Òò×ӵĸıäµÈ ¡£ÕâЩ֤¾Ý×ÛºÏÅú×¢£¬Ó×ÄêÊ󸹲ຣÂí»ÙËðµ¼ÖÂƤ²ãDA£­¹È°±Ëá-GABAÏ໥×÷Óõĸı䣬¶øÕâЩ¸Ä±äͬÑùÌåÏÖÔÚ¾«ÉñÆÆËéÖ¢»¼ÕßÉíÉÏ ¡£Í¬Ê±£¬Ðí¶à¿¹¾«ÉñÆÆËéÖ¢Ò©ÎïÄæתÁËÓ×Äê´óÊ󸹲ຣÂí»ÙËðºóÔÚ³ÉÄ걬·¢µÄ²¡ÀíÐÄÀí¸Ä±ä ¡£×ÜÖ®£¬Ó×Äê´óÊ󸹲ຣÂí»ÙËðÄ£×ÓÄܹ»ÓÕ·¢Ó뾫ÉñÆÆËéÖ¢Ö¢×´ÏàÀàËƵÄÕÏ°­£¬ÔÚÒ»¶¨Ë®Æ½ÉÏÑéÖ¤Á˾«ÉñÆÆËéÖ¢Éñ¾­·¢ÓýÕÏ°­µÄ¼Ù˵ ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.ÍõÏþÁ¼£®´Þ¶«ºì£¬ËÚÓ×áÔ£®¶¯ÎïÄ£×ÓÔÚ¾«ÉñÆÆËéÖ¢Ñо¿ÖеÄÓ¦ÓÃÓëÏ£Íû£®ÖйúÒ½Ò©µ¼±¨£¬2012,9 (30):23-26

2.ÀîÏþ°×£¬·½êÝÈ壬Íõ×æ³Ð£¬µÈ£®¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®ÉϺ£¾«Éñҽѧ£¬2004, 16(3): 184-186

3.Bertaina-Anglade V,Enjuanes E,Morillon D,el al. The object recognition Lask in rats anrl mice:a simple and rapid model in safety pharmacology lo detect amnesi properties of a new chemical entity. J Pharmacol Toxicol Methods, 2006, 54 (2):99-105

4.Jentsch JD, Roth RH. The neuropsypharmacology of phencyclidine: from NMDA receptor  hypofunction  lo the dopamine hypothesis of schizophrenia. Neurops-ychopharmacology, 1999,20 (3):201 -225

5.Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol psychosis, 2001, 50 (11):845-855

6.Li Q,Cheung C, Wei R,el al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant lo schizophrenia:evidence from MRI in a mouse model. PLoS One,2009,4(7):e6354

7.Semenova S,Ceyer MA,Sutcliffe JC,et al. Inaclivalion of the 5-HT7 receptor partiality blocks phencyclidineinduced disruption of prepulse inhibition. Biol Psychiatry, 2008, 63 (1):98-105

8.van Elst LT, Valerius G,Buchert M,et al. Incrased prefrontal and hippocampal glutamate  concentration in schizophrenia:evidence from a magnetic resonance pectroscopy study. Biol Psychiatry, 2005,58 (9):724-730

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > Éñ¾­·¢Óý¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó
Éñ¾­·¢Óý¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó

Ç°ÑÔ

Éñ¾­·¢ÓýÕÏ°­¼Ù˵ÒÔΪ£¬¾«ÉñÆÆËéÖ¢Ô´ÓÚÔçÆÚµÄÄÔËðÉË ¡£ÁÙ´²ÉÏ£¬¾«ÉñÆÆËéÖ¢·¢²¡ÓÚÇà׳Ä꣬ÓпÉÄÜÊÇÓÉÓÚÔçÆÚ´óÄÔËðÉ˵IJ¿Î»ÓëÕý³£·¢ÓýµÄÖÐÊàÉñ¾­ÏµÍ³Ö®¼äµÄÏ໥×÷ÓÃËù±¬·¢µÄ ¡£´óÄÔ·¢ÓýÉв»¿ÉÊì¶øÔâÓöËðÉ˵ÄÇéÐÎÏ£¬ÊÜËðÉ˲¿Î»½«ÔÚÒÔºóµÄ·¢ÓýÖиıäÓë´óÄÔÆäËû²¿Î»µÄÍŽ᷽·¨£¬¶ø±¬·¢Òì³£µÄÉñ¾­ÁªÂ磬ÕâÖÖÒì³£ÔÚ´óÄÔ·¢Óý³ÉÊìʱ±ãÌåÏÖ³öÀ´ ¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÃһϵÁÐÒªÁì¶ÔÐÂÉú´óÊó»ò·ÇÈËÁ鳤ÀàijЩÌض¨ÄÔÇøËð»Ù£¬Ö÷ÒªÊÇÆÆËðº£Âí·¢Óý£¬´Ó¶øÆÆËðº£Âí¼ÓÈëµÄÆÕ±éµÄƤÖʺÍƤÖÊÏÂÉñ¾­»·Â· ¡£ÕâЩËðÉË°üÀ¨Ö±½ÓͶÉ䵽ǰ¶îҶƤÖʵĺ£ÂíÇøÓò£¨È縹²àº£ÂíºÍ¸¹²àÏÂÍУ©£¬ÕâЩ²¿Î»¾ùÓ뾫ÉñÆÆËéÖ¢µÄ·¢²¡Ç×½üÏà¹Ø ¡£

¡¾Ä£×ÓÌص㡿£º

×дóÊ󸹲ຣÂí»ÙËðÄ£×ÓÒòº£ÂíµÄÐ˷ܶ¾ÐԵĻÙË𣬶øµ¼Ö³ÉÄê´óÊóÔÚÉñ¾­µÝÖʺÍÐÐΪ·½Ã汬·¢¸Ä±ä£¬ÈçÉç»áÐÔ½Ó´¥ÐÐΪïÔÌ­¡¢ÊÂÇéÓ°ÏóÕÏ°­¡¢¶ÔÓ¦¼¤ÐԴ̼¤µÄ¹ý¶àÐж¯ºÍ¿Ì°åÐÐΪµÄÔöÌí ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

Ó×Äê´óÊ󸹲ຣÂí»ÙËðÔÚÇ°¶îҶƤ²ã±¬·¢ÁËһϵÁеIJ¡ÀíÐԸı䣬È磬ÒÒõ£Ì춬°±ËáˮƽµÄϽµ¡¢Ó¦¼¤ÓÕ·¢¶à°Í°·(DA)ÊÍ·ÅϽµ¡¢¹È°±ËáתÔËÌåEAAC1Ƥ²ã±í´ïµÄïÔÌ­¡¢γ-°±»ù¶¡Ëá(gamma-amino butyric acid,GABA)ºÏ³ÉøïÔÌ­¡¢¹È°±ËáÍÑôÈøµÄïÔÌ­¡¢ÄÔÔ´ÐÔÉñı»®ÑøÒò×Ó(BDNF)µÄïÔÌ­¼°Ä³Ð©»ùÒòת¼Òò×ӵĸıäµÈ ¡£ÕâЩ֤¾Ý×ÛºÏÅú×¢£¬Ó×ÄêÊ󸹲ຣÂí»ÙËðµ¼ÖÂƤ²ãDA£­¹È°±Ëá-GABAÏ໥×÷Óõĸı䣬¶øÕâЩ¸Ä±äͬÑùÌåÏÖÔÚ¾«ÉñÆÆËéÖ¢»¼ÕßÉíÉÏ ¡£Í¬Ê±£¬Ðí¶à¿¹¾«ÉñÆÆËéÖ¢Ò©ÎïÄæתÁËÓ×Äê´óÊ󸹲ຣÂí»ÙËðºóÔÚ³ÉÄ걬·¢µÄ²¡ÀíÐÄÀí¸Ä±ä ¡£×ÜÖ®£¬Ó×Äê´óÊ󸹲ຣÂí»ÙËðÄ£×ÓÄܹ»ÓÕ·¢Ó뾫ÉñÆÆËéÖ¢Ö¢×´ÏàÀàËƵÄÕÏ°­£¬ÔÚÒ»¶¨Ë®Æ½ÉÏÑéÖ¤Á˾«ÉñÆÆËéÖ¢Éñ¾­·¢ÓýÕÏ°­µÄ¼Ù˵ ¡£

 

 

²Î¿¼ÎÄÏ×£º

1.ÍõÏþÁ¼£®´Þ¶«ºì£¬ËÚÓ×áÔ£®¶¯ÎïÄ£×ÓÔÚ¾«ÉñÆÆËéÖ¢Ñо¿ÖеÄÓ¦ÓÃÓëÏ£Íû£®ÖйúÒ½Ò©µ¼±¨£¬2012,9 (30):23-26

2.ÀîÏþ°×£¬·½êÝÈ壬Íõ×æ³Ð£¬µÈ£®¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®ÉϺ£¾«Éñҽѧ£¬2004, 16(3): 184-186

3.Bertaina-Anglade V,Enjuanes E,Morillon D,el al. The object recognition Lask in rats anrl mice:a simple and rapid model in safety pharmacology lo detect amnesi properties of a new chemical entity. J Pharmacol Toxicol Methods, 2006, 54 (2):99-105

4.Jentsch JD, Roth RH. The neuropsypharmacology of phencyclidine: from NMDA receptor  hypofunction  lo the dopamine hypothesis of schizophrenia. Neurops-ychopharmacology, 1999,20 (3):201 -225

5.Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol psychosis, 2001, 50 (11):845-855

6.Li Q,Cheung C, Wei R,el al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant lo schizophrenia:evidence from MRI in a mouse model. PLoS One,2009,4(7):e6354

7.Semenova S,Ceyer MA,Sutcliffe JC,et al. Inaclivalion of the 5-HT7 receptor partiality blocks phencyclidineinduced disruption of prepulse inhibition. Biol Psychiatry, 2008, 63 (1):98-105

8.van Elst LT, Valerius G,Buchert M,et al. Incrased prefrontal and hippocampal glutamate  concentration in schizophrenia:evidence from a magnetic resonance pectroscopy study. Biol Psychiatry, 2005,58 (9):724-730

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿